Longevity - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The longevity market size is expected to grow from USD 29.77 billion in 2025 to USD 31.63 billion in 2026 and is forecast to reach USD 46.86 billion by 2031 at 8.18% CAGR over 2026-2031. This report is Segmented by Therapy (Senolytic Small Molecules, Senomorphic Agents, Gene Therapy, and More), Delivery Platform (In-Vivo Therapeutics, and More), Application (Cardiovascular Diseases, Neurodegenerative Disorders, and More), End User (Pharmaceutical & Biotechnology Companies, and More), and Geography (North America, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Longevity Market Trends and Insights

Rapid Rise in the 65+ Population

The United Nations projects a global cohort of 1.6 billion people aged 65 and older by 2050, more than doubling the 761 million counted in 2021. According to a 2024 United Nations update, by the mid-2030s, the number of individuals aged 80 and older is set to hit 265 million, and by the late 2070s, those aged 65 and older will soar to 2.2 billion globally. Japan, where 29% of residents were over 65 in 2024, funds Silver Human Resources Centers that standardize longevity diagnostics in routine geriatric visits, and similar reimbursement pilots are under review in several European Union member states.China’s 14th Five-Year Plan assigns CNY 3.2 trillion to eldercare infrastructure, opening hospital-based pilot programs that test senolytics for frailty reduction. Medicare, meanwhile, spends USD 23,000 per beneficiary each year managing chronic disease clusters in older adults; actuarial models show that compressing morbidity via senescent-cell clearance could materially lower lifetime outlays. The World Health Organization’s Decade of Healthy Ageing has unlocked multilateral funding streams, giving longevity science formal standing as a public-health priority.

Growing Burden of Age-Related Chronic Diseases

Cardiovascular disease, cancer, neurodegeneration, and metabolic syndrome drive 71% of all deaths worldwide. Alzheimer’s disease alone consumed USD 345 billion in U.S. health expenditures in 2024, and CMS agreed to reimburse lecanemab using an accelerated pathway that links coverage to post-marketing safety surveillance. Preclinical research shows dasatinib-plus-quercetin clears senescent cells in idiopathic pulmonary fibrosis and osteoarthritis, yet translation slows without biomarkers that quantify senescent burden in human tissue. Global diabetes prevalence will top 700 million cases by 2045, with beta-cell senescence becoming a viable pharmacologic target alongside GLP-1 receptor agonists. Draft EMA guidance published in 2024 signals regulatory openness to geroprotectors if functional gain across multiple organ systems is proven.

Regulatory Ambiguity Over Classifying Aging as a Disease

The FDA treats aging as a risk factor rather than a diagnosable indication, compelling sponsors to pivot toward proxy endpoints such as frailty or metabolic syndrome. The multi-center TAME study seeks precedent for labeling metformin as an age-delaying therapy but remains in progress through 2026. EMA draft guidance in 2024 hinted that functional gains across organ systems could satisfy approval criteria, yet lack of validated surrogate biomarkers slows adoption. Japan’s PMDA takes a looser stance, approving NMN supplements as functional foods, offering a partial workaround that falls short of prescription-drug rigor. ICD-11 now lists an extension code for aging-related decline in intrinsic capacity, but national uptake remains uneven.

Other drivers and restraints analyzed in the detailed report include:

• Venture Capital and SPAC Surge in Rejuvenation Biotech
• Breakthroughs in CRISPR and Gene-Editing Tools
• High Clinical-Trial Costs and Multi-Year Timelines

Segment Analysis

Gene therapy will post an 11.63% CAGR through 2031, the fastest rate among modalities, helped by adeno-associated-virus refinements that permit repeat dosing in chronic degenerative conditions. Senolytic small molecules held 36.52% of revenue in 2025, cementing their position as the largest contributor to the longevity market. First-generation agents face off-target toxicity, which catalyzes a shift toward senomorphic compounds that limit SASP emissions without triggering apoptosis. Rapalog trials in metabolic syndrome showed a 30% inflammatory-marker drop, reinforcing the therapeutic logic of pathway modulation rather than cell clearance. Cellular reprogramming remains preclinical but garners high investment, especially with Altos Labs advancing retinal-degeneration protocols toward IND filings. Stem-cell infusions benefit from Japan’s fast-track approvals for frailty, while immunotherapies targeting inflammaging encounter safety trade-offs tied to cytokine suppression. Microbiome manipulation, including Mitopure’s GRAS-cleared urolithin A, rounds out the pipeline with consumer-facing nutraceutical angles.

In aggregate, the longevity market size for gene therapy is poised to expand from a low starting base, while senolytic small molecules retain the highest longevity market share in the short term. Cross-modality combinations such as senolytic preconditioning before gene therapy are under preclinical review and may re-shape competitive hierarchies after 2030.

In-vivo therapeutics captured 71.83% of 2025 revenue, powered by small molecules and systemically administered biologics. Yet digital longevity interventions, which include epigenetic clocks and wearable biomarker platforms, are forecast to grow 12.78% annually, the fastest pace of any platform. Insurer pilots that reimburse biological-age reduction underpin the commercial logic for these data-driven tools. Ex-vivo cell-based approaches, validated by Casgevy’s approval, remain capital intensive but are likely to gain share as manufacturing efficiencies improve.

The longevity market size for digital platforms could outpace expectations if payor pilots convert to full reimbursement policies. Conversely, in-vivo developers protect their dominant longevity market share by layering digital endpoints onto drug trials, forming hybrid models that blend therapeutics with real-time monitoring.

Complete Report Scope:

• By Therapy
  • Senolytic Small Molecules
  • Senomorphic Agents
  • Gene Therapy
  • Cellular Reprogramming Therapy
  • Stem Cell & Regenerative Therapy
  • Immunotherapy
  • Microbiome Manipulation
  • Others
• By Delivery Platform
  • In-vivo Therapeutics
  • Ex-vivo / Cell-based Platforms
  • Digital Longevity Interventions
• By Application
  • Cardiovascular Diseases
  • Neurodegenerative Disorders
  • Metabolic Disorders (Diabetes, Obesity)
  • Oncological Indications
  • Musculoskeletal & Frailty
  • Dermatology & Aesthetics
  • Ophthalmology
  • Others
• By End User
  • Pharmaceutical & Biotechnology Companies
  • Academic & Research Institutes
  • CROs & CDMOs
  • Wellness Clinics & Longevity Spas
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America generated 41.23% of 2025 revenue, buoyed by NIH’s USD 3.7 billion aging-research allocation and steady venture financing in Silicon Valley. The United States lists more than 120 longevity trials, although regulatory ambiguity tempers speed to market. Canada’s CAD 30 million Stem Cell Network grant fosters regenerative-frailty studies, and Mexico’s proximity to the U.S. pulls medical tourists seeking stem-cell therapies.

Asia-Pacific is on course for a 10.35% CAGR through 2031. Japan integrates longevity diagnostics within universal coverage, China funds CNY 16 trillion in preventive infrastructure, and India scales elder-care programs despite uneven access to advanced therapies. South Korea and Australia finalize guidance that clarifies aging-therapy pathways, drawing biotechs that seek faster approvals.

Europe sits mid-pack, but EMA’s permissive stance toward multi-system endpoints could accelerate approvals. Switzerland’s dense cluster of premium clinics attracts global clientele, while the NHS tests whether early pharmacologic and lifestyle interventions reduce multimorbidity by 2034. The Middle East and Africa remain emergent; the UAE licenses stem-cell clinics under compassionate-use rules, and South Africa green-lights MSC therapies for frailty.

List of Companies Covered in this Report:

• Abbvie
• AgeX Therapeutics
• Altos Labs
• BioAge Labs
• Bristol-Myers Squibb
• Calico Life Sciences
• Cambrian BioPharma
• Clover Therapeutics
• CohBar Inc.
• Eli Lilly and Company
• FoxBio
• GlaxoSmithKline
• Insilico Medicine
• Juvenescence Ltd.
• Life Biosciences
• Merck
• Oisín Biotechnologies
• Pfizer
• Rejuvenate Bio
• Revel Pharmaceuticals
• Serina Therapeutics
• TheraSyn
• Turn.Bio
• Unity Biotechnology

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support